Saturday 17 October 2026
Export HKPD’s income statement to Excel — free account
Cellyan Biotechnology Co., Ltd
HKPD Healthcare Medical Distribution
Cellyan Biotechnology Co., Ltd’s revenue for fiscal 2026 (year ended March 2026) was $13.4 million, down 33.9% from fiscal 2025.
0.11
0.00
0.00%
Follow HKPD
| Older periods | Sep '24 | Mar '25 | Sep '25 | Mar '26 | |
|---|---|---|---|---|---|
Current Ratio |
+2 more quarters Free account |
2.46 | 2.99 | 2.93 | 3.86 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
14.16% | 19.99% | 18.89% | 7.34% | |
Debt/Equity |
0.27 | 0.38 | 0.35 | 0.10 | |
Asset Turnover |
— | — | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(3.12) | (0.92) | (0.90) | (0.41) | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
0.65 | 0.50 | (0.29) | (0.79) | |
Working Capital |
5.28 | 5.81 | 5.83 | 9.14 | |
Capital Expenditures |
(0.11) | (0.07) | (0.04) | (0.04) | |
Net Current Asset Value |
4.07 | 4.30 | 4.37 | 9.07 | |
| Other line items | |||||
Quick Ratio |
1.71 | 2.80 | 2.73 | 3.75 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
— | — | 3.91 | 8.37 | |
Average Payables |
— | — | 1.39 | 1.15 | |
Average Inventory |
— | — | 0.39 | 0.65 | |
Average Assets |
— | — | 6.52 | 10.76 | |
Average Common Equity |
— | — | 2.86 | 6.92 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates